Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Pharming Group    PHARM   NL0010391025

PHARMING GROUP

(PHARM)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
05/17/2019 05/20/2019 05/21/2019 05/22/2019 05/23/2019 Date
0.79(c) 0.7884(c) 0.8044(c) 0.7922(c) 0.759 Last
10 051 991 4 113 257 6 033 001 6 114 407 8 428 739 Volume
-1.89% -0.20% +2.03% -1.52% -4.19% Change
More quotes
Financials (EUR)
Sales 2019 162 M
EBIT 2019 53,2 M
Net income 2019 28,7 M
Finance 2019 6,15 M
Yield 2019 -
Sales 2020 200 M
EBIT 2020 75,5 M
Net income 2020 60,8 M
Finance 2020 29,4 M
Yield 2020 -
P/E ratio 2019 17,22
P/E ratio 2020 9,18
EV / Sales2019 3,00x
EV / Sales2020 2,31x
Capitalization 492 M
More Financials
Company
Pharming Group specializes in the development of innovative products for the treatment of genetic disorders, specialty products for surgical indications, and nutritional products. The group's technologies include innovative platforms for the production of protein therapeutics, as well as technology... 
Sector
Biotechnology & Medical Research
Calendar
05/22 | 08:00amShareholder meeting
More about the company
Surperformance© ratings of Pharming Group
Trading Rating : Investor Rating :
More Ratings
Latest news on PHARMING GROUP
05/13PHARMING GROUP N.V. : quaterly earnings release
04/09PHARMING : announces completion of minority investment in BioConnection BV Pharm..
PU
03/29PHARMING : Press releaseMarch 28 Pharming Group announces publication of its Ann..
PU
03/04PHARMING GROUP N.V. : annual earnings release
2018PHARMING : Dutch biotech Pharming plans to challenge big pharma in rare diseases
AQ
2018PHARMING : reports favourable conclusion from first investigator-initiated direc..
PU
2018PHARMING : reports interim financial results for the first nine months of 2018
PU
2018PHARMING : Reports Positive Data From First Investigator-initiated Study of rhC1..
AQ
2018PHARMING : reports positive data from first investigator-initiated study of rhC1..
PU
2018PHARMING : FDA rejects Pharmings Ruconest HAE label expansion
AQ
More news
Analyst Recommendations on PHARMING GROUP
More recommendations
Sector news : Biotechnology & Medical Research - NEC
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PHARMING GROUP
Duration : Period :
Pharming Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMING GROUP
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 1,66 €
Spread / Average Target 109%
EPS Revisions
Managers
NameTitle
Sijmen de Vries Chief Executive Officer
Paul Jai Sekhri Chairman-Supervisory Board
Bruno M. L. Giannetti Chief Operations Officer
Robin Wright Chief Financial Officer
Erica Kerkvliet Senior Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PHARMING GROUP4.58%549
IQVIA HOLDINGS INC15.84%26 365
LONZA GROUP23.56%22 847
CELLTRION, INC.--.--%20 193
INCYTE CORPORATION24.26%16 475
EXACT SCIENCES CORPORATION53.65%12 402